TCT-171 Clinical Outcomes Using Prasugrel or Ticagrelor Based On Physician Treatment Decisions In Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Comparative Results Using Propensity Analysis Of A Payer Database

Authors :: Brian R. Murphy
Yajun Zhu
Beth L. Nordstrom
George W. Vetrovec
Cliff Molife
Jason C. Simeone
Stuart Keller
Mark B. Effron
Robert L. Page
Kavita V. Nair
Patrick L. McCollam
Source :: Journal of the American College of Cardiology. 66(15):B63-B64
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.
Abstract: Prasugrel and ticagrelor are potent P2Y12 ADP receptor inhibitors that have greater clinical efficacy compared with clopidogrel, but more non-CABG bleeding. There are no direct comparisons of clinical outcomes between the drugs with follow-up through 1 year. This retrospective study compared 1 year

Subjects :: medicine.medical_specialty
Acute coronary syndrome
Prasugrel
business.industry
medicine.medical_treatment
Percutaneous coronary intervention
Retrospective cohort study
medicine.disease
Clopidogrel
P2Y12
Internal medicine
medicine
In patient
cardiovascular diseases
business
Intensive care medicine
Cardiology and Cardiovascular Medicine
Ticagrelor
medicine.drug

Full Text Access

Tools